Advertisement
Advertisement
LCTX
Lineage Cell Therapeutics, Inc.
1.28
USDSponsored
-0.05
-3.76%
May 13, 16:00 UTC -4
Closed
Pre-Market
1.30
+0.02
+1.56%
LCTX Earnings Reports
Positive Surprise Ratio
LCTX beat 23 of 42 last estimates.
55%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$6.21M
/-$0.01
Implied change from Q1 26 (Revenue/ EPS)
+259.18%
/-66.67%
Implied change from Q2 25 (Revenue/ EPS)
+124.73%
/-85.71%
Lineage Cell Therapeutics, Inc. earnings per share and revenue
On May 12, 2026, LCTX reported earnings of -0.03 USD per share (EPS) for Q1 26, missing the estimate of -0.02 USD, resulting in a -47.06% surprise. Revenue reached 1.73 million, compared to an expected 3.67 million, with a -52.91% difference. The market reacted with a -3.76% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.01 USD, with revenue projected to reach 6.21 million USD, implying an decrease of -66.67% EPS, and increase of 259.18% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Lineage Cell Therapeutics, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Lineage Cell Therapeutics, Inc. reported EPS of -$0.03, missing estimates by -47.06%, and revenue of $1.73M, -52.91% below expectations.
How did the market react to Lineage Cell Therapeutics, Inc.'s Q1 2026 earnings?
The stock price moved down -3.76%, changed from $1.33 before the earnings release to $1.28 the day after.
When is Lineage Cell Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Lineage Cell Therapeutics, Inc.'s next earnings report?
Based on 7
analysts, Lineage Cell Therapeutics, Inc. is expected to report EPS of -$0.01 and revenue of $6.21M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement